



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

VAN ANDEL INSTITUTE JOINS THE METAMINER ONCOLOGY PARTNERSHIP PROGRAM

St. Joseph, MI. March 31st, 2009 –GeneGo, Inc., the leading systems biology tools company, announced today that Craig Webb, Ph.D., director of the Program of Translational Medicine at Grand Rapids, Mich.-based Van Andel Institute, has joined the MetaMiner Oncology Partnership Program.

The goal of the program is to develop a proprietary oncology pathway analysis platform built by experts in the field. This includes developing a series of blueprint pathway maps for cancers, collecting public domain experimental data and normalizing, parsing and making it available for use, as well as developing cancer specific ontologies.

“We feel that it is important to support such an initiative. There is an increasing amount of information in the cancer literature but no one has brought it all together in a set of comprehensive pathway maps that can be further explored,” said Webb “This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly.”

Van Andel Institute announced in February an alliance and affiliation agreement with the Phoenix-based Translational Genomics Research Institute (TGen), one of the preeminent translational research organizations in the biomedical industry.

“Craig does amazing work at VAI, working with late-stage cancer patients to give them hope, and we are pleased to have him on our team,” said Julie Bryant, GeneGo’s VP of Business Development. “We have a lot of experience in cancer and have received millions of dollars in grants to fund our pioneering research.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product,

MetaCore 5.2™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About Van Andel Institute

Established by Jay and Betty Van Andel in 1996, Van Andel Institute (VAI) is an independent research and educational organization based in Grand Rapids, Mich., dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. Van Andel Research Institute (VARI), the research arm of VAI, is dedicated to probing the genetic, cellular and molecular origins of cancer, Parkinson and other diseases and working to translate those findings into effective therapies. This is accomplished through the work of over 200 researchers in 18 on-site laboratories, in laboratories in Singapore and Nanjing, and in collaborative partnerships that span the globe. *For additional information, visit: www.vai.org.*